Your Window to Precision Biomarkers

We are revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs, and better outcomes. Our AI-enabled EV-Omics (EVO) platform enriches disease-associated extracellular vesicles (EVs)—through EVO, we offer reliable, blood-based discovery and detection of protein and RNA biomarkers.

image description

The FYR Benefit

  • Specialized Applications

    Liquid biopsies for neurodegeneration, neuro-oncology, and antibody drug conjugate (ADC) applications

  • Multiomics-First Approach

    Leveraging the power of DNA, RNA, and protein data from extracellular vesicles for comprehensive multiomics insights of biology and disease

  • Partnerships

    Clinical trial support, biomarker discovery, biomarker validation, translation of tissue markers to plasma

The FYR Difference, Igniting Your Success

Our breakthrough EVO Platform employs SPARCs to enrich disease or tissue-associated EV subpopulations. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanism. This unparalleled view provided by our multiomics approach can transform drug development and precision medicine. Our team can be your partner at every stage of the drug development process and help your company upgrade its biomarker discovery and detection capabilities. We’re here to help at every step along the way.

  • Novel Technologies

    • EVO-Platform™: Comprehensive multiomics approach, combining genomics, transcriptomics, and proteomics data to reveal disease and biomarker insights. Focus on EVs for advanced disease detection and monitoring through both liquid and traditional tissue biopsies.
    • SPARCs™: Selective Protein Affinity Reagent Chemistries, designed to isolate specific disease or tissue-associated EV subpopulations, enriching vital biomarkers for more accurate and early disease detection.
    • Advanced Machine Learning & Analytics.
  • Transforming Drug Development

    • Increase the effectiveness of clinical trial design and management
    • Identify markers of disease with enhanced sensitivity
    • Increase the understanding of disease mechanisms and treatment responses
    • Provide longitudinal insights into treatment response/ disease progression
    • Measure the mechanisms of action of your drug through pharmacodynamics
    • Increase the effectiveness of clinical trial design and management
    • Detect early markers of disease
    • Identify novel drug targets

FYRed Up About Partnering With Us?

Have we sparked your interest in partnering with us? We fuel new relationships, collaborations, and strategic partnerships. Let’s kindle the next generation of innovation together. To learn more about our services or to receive a quote, contact us.

Contact us